Harnessing Fc receptor biology in the design of therapeutic antibodies

Current Opinion in Immunology

Volumn 40, Issue , 2016, Pages 78-87

  Sondermann, Peter ^a   Szymkowski, David E ^b  

^a Baxalta Incorporated   (Germany)

^b Xencor Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BENRALIZUMAB; BEVACIZUMAB; CERTOLIZUMAB PEGOL; ECULIZUMAB; ETANERCEPT; FC RECEPTOR; GOLIMUMAB; INFLIXIMAB; IPILIMUMAB; MOGAMULIZUMAB; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OMALIZUMAB; PLACEBO; QUILIZUMAB; SM 101; TICILIMUMAB; UNCLASSIFIED DRUG; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

ALLERGIC ASTHMA; ALLERGIC DISEASE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ASTHMA; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG DESIGN; DRUG HALF LIFE; EFFECTOR CELL; GENE MUTATION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSTIMULATION; NONHUMAN; PROTEIN ENGINEERING; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL DEPLETION; ANIMAL; GENETICS; IMMUNOTHERAPY; METABOLISM; PROCEDURES; SIGNAL TRANSDUCTION; TRENDS;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG DESIGN; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOTHERAPY; PROTEIN ENGINEERING; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

EID: 84962208068     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2016.03.005     Document Type: Review

References (92)

1. Ecker D.M., Jones S.D., Levine H.L. The therapeutic monoclonal antibody market. mAbs 2015, 7:9-14.
2. Zolot R.S., Basu S., Million R.P. Antibody-drug conjugates. Nat Rev Drug Discov 2013, 12:259-260.
3. Unkeless J.C., Scigliano E., Freedman V.H. Structure and function of human and murine receptors for IgG. Annu Rev Immunol 1988, 6:251-281.
4. Ravetch J.V., Kinet J.P. Fc receptors. Annu Rev Immunol 1991, 9:457-492.
5. Hogarth P.M., Pietersz G.A. Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond. Nat Rev Drug Discov 2012, 11:311-331.
6. Elvin J.G., Couston R.G., van der Walle C.F. Therapeutic antibodies: market considerations, disease targets and bioprocessing. Int J Pharm 2013, 440:83-98.
7. Anderson C.L., Ganesan L.P., Robinson J.M. The biology of the classical Fcγ receptors in non-hematopoietic cells. Immunol Rev 2015, 268:236-240.
8. Nimmerjahn F., Gordan S., Lux A. FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends Immunol 2015, 36:325-336.
9. Koene H.R., Kleijer M., Algra J., Roos D., von dem Borne A.E.K., de Haas M. FcγRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcγRIIIa, independently of the FcγRIIIa-48L/R/H phenotype. Blood 1997, 90:1109-1114.
10. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002, 99:754-758.
11. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Capelletti M., Missale G., Laccabue D., Zerbini A., Camisa R., Bisagni G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008, 26:1789-1796.
12. Biburger M., Lux A., Nimmerjahn F. How immunoglobulin G antibodies kill target cells: revisiting an old paradigm. Adv Immunol 2014, 124:67-94.
13. Farag S.S., Flinn I.W., Modali R., Lehman T.A., Young D., Byrd J.C. FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. Blood 2004, 103:1472-1474.
14. Lin T.S., Flinn I.W., Modali R., Lehman T.A., Webb J., Waymer S., Moran M.E., Lucas M.S., Farag S.S., Byrd J.C. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood 2005, 105:289-291.
15. Shields R.L., Namenuk A.K., Hong K., Meng Y.G., Rae J., Briggs J., Xie D., Lai J., Stadlen A., Li B., et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem 2001, 276:6591-6604.
16. Stavenhagen J.B., Gorlatov S., Tuaillon N., Rankin C.T., Li H., Burke S., Huang L., Vijh S., Johnson S., Bonvini E., et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors. Cancer Res 2007, 67:8882-8890.
17. Lazar G.A., Dang W., Karki S., Vafa O., Peng J.S., Hyun L., Chan C., Chung H.S., Eivazi A., Yoder S.C., et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A 2006, 103:4005-4010.
18. Richards J.O., Karki S., Lazar G.A., Chen H., Dang W., Desjarlais J.R. Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008, 7:2517-2527.
19. Jurczak W., Zinzani P.L., Goy A., Provencio M., Nagy Z., Robak T., Maddocks K.J., Buske C., Korolkiewicz R., Winderlich M. Phase IIa study of single-agent MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). ASCO Annual Meeting Proceedings 2015, 8500.
20. Kellner C., Zhukovsky E.A., Potzke A., Bruggemann M., Schrauder A., Schrappe M., Kneba M., Repp R., Humpe A., Gramatzki M., et al. The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients. Leukemia 2013, 27:1595-1598.
21. Zalevsky J., Leung I.W., Karki S., Chu S.Y., Zhukovsky E.A., Desjarlais J.R., Carmichael D.F., Lawrence C.E. The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates. Blood 2009, 113:3735-3743.
22. ® 2513 in patients with relapsed or refractory Hodgkin lymphoma. Br J Haematol 2015, 168:902-904.
23. Lee E.M., Yee D., Busfield S.J., McManus J.F., Cummings N., Vairo G., Wei A., Ramshaw H.S., Powell J.A., Lopez A.F., et al. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice. Haematologica 2015, 100:914-926.
24. Li G., Zhang L., Chen E., Wang J., Jiang X., Chen J.H., Wickman G., Amundson K., Bergqvist S., Zobel J., et al. Dual functional monoclonal antibody PF-04605412 targets integrin α5β1 and elicits potent antibody-dependent cellular cytotoxicity. Cancer Res 2010, 70:10243-10254.
25. Heider K.H., Kiefer K., Zenz T., Volden M., Stilgenbauer S., Ostermann E., Baum A., Lamche H., Kupcu Z., Jacobi A., et al. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 2011, 118:4159-4168.
26. DiLillo D.J., Ravetch J.V. Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell 2015, 161:1035-1045.
27. Van der Neut Kolfschoten M., Schuurman J., Losen M., Bleeker W.K., Martínez-Martínez P., Vermeulen E., Den Bleker T.H., Wiegman L., Vink T., Aarden L.A. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007, 317:1554-1557.
28. Beck A., Reichert J.M. Marketing approval of mogamulizumab: a triumph for glyco-engineering. mAbs 2012, 4:419-425.
29. Hoy S.M. Obinutuzumab: a review of its use in patients with chronic lymphocytic leukaemia. Drugs 2015, 75:285-296.
30. Ghazi A., Trikha A., Calhoun W.J. Benralizumab - a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity - a novel approach for the treatment of asthma. Expert Opin Biol Ther 2012, 12:113-118.
31. Gauvreau G.M., Harris J.M., Boulet L.-P., Scheerens H., Fitzgerald J.M., Putnam W.S., Cockcroft D.W., Davis B.E., Leigh R., Zheng Y. Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production. Sci Transl Med 2014, 6:243ra285.
32. Beck A., Wagner-Rousset E., Bussat M.C., Lokteff M., Klinguer-Hamour C., Haeuw J.F., Goetsch L., Wurch T., Van Dorsselaer A., Corvaia N. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharm Biotechnol 2008, 9:482-501.
33. von Horsten H.H., Ogorek C., Blanchard V., Demmler C., Giese C., Winkler K., Kaup M., Berger M., Jordan I., Sandig V. Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-d-lyxo-4-hexulose reductase. Glycobiology 2010, 20:1607-1618.
34. Gardai S.J., Epp A., Linares G., Westendorf L., Sutherland M., Neff-LaFord H., Peng S.L., Law C.-L. SEA-CD40, a sugar engineered non-fucosylated anti-CD40 antibody with improved immune activating capabilities. Cancer Res 2015, 75:2472.
35. Lehmann B., Schwab I., Bohm S., Lux A., Biburger M., Nimmerjahn F. FcγRIIB: a modulator of cell activation and humoral tolerance. Expert Rev Clin Immunol 2012, 8:243-254.
36. Chu S.Y., Vostiar I., Karki S., Moore G.L., Lazar G.A., Pong E., Joyce P.F., Szymkowski D.E., Desjarlais J.R. Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies. Mol Immunol 2008, 45:3926-3933.
37. Mimoto F., Katada H., Kadono S., Igawa T., Kuramochi T., Muraoka M., Wada Y., Haraya K., Miyazaki T., Hattori K. Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131). Protein Eng Des Sel 2013, 26:589-598.
38. Chu S.Y., Yeter K., Kotha R., Pong E., Miranda Y., Phung S., Chen H., Lee S.H., Leung I., Bonzon C., et al. Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor. Arthritis Rheumatol 2014, 66:1153-1164.
39. Horton H.M., Chu S.Y., Ortiz E.C., Pong E., Cemerski S., Leung I.W., Jacob N., Zalevsky J., Desjarlais J.R., Stohl W. Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol 2011, 186:4223-4233.
40. Meeker T.C., Miller R.A., Link M.P., Bindl J., Warnke R., Levy R. A unique human B lymphocyte antigen defined by a monoclonal antibody. Hybridoma 1984, 3:305-320.
41. Veri M.C., Burke S., Huang L., Li H., Gorlatov S., Tuaillon N., Rainey G.J., Ciccarone V., Zhang T., Shah K. Therapeutic control of B cell activation via recruitment of Fcγ receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum 2010, 62:1933-1943.
42. ® molecules for the treatment of autoimmune disorders (THER5P.830). J Immunol 2014, 192:200-209.
43. Rieth N., Carle A., Muller M.A., ter Meer D., Direnberger C., Pohl T., Sondermann P. Characterization of SM201, an anti-hFcγRIIB antibody not interfering with ligand binding that mediates immune complex dependent inhibition of B cells. Immunol Lett 2014, 160:145-150.
44. Chu S.Y., Horton H.M., Pong E., Leung I.W., Chen H., Nguyen D.H., Bautista C., Muchhal U.S., Bernett M.J., Moore G.L., et al. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody. J Allergy Clin Immunol 2012, 129:1102-1115.
45. Ganesan L.P., Kim J., Wu Y., Mohanty S., Phillips G.S., Birmingham D.J., Robinson J.M., Anderson C.L. FcγRIIb on liver sinusoidal endothelium clears small immune complexes. J Immunol 2012, 189:4981-4988.
46. Biburger M., Aschermann S., Schwab I., Lux A., Albert H., Danzer H., Woigk M., Dudziak D., Nimmerjahn F. Monocyte subsets responsible for immunoglobulin G-dependent effector functions in vivo. Immunity 2011, 35:932-944.
47. Moore G., Chu S., Pong E., Wickramarachchi D., Endo N., Chan E., Phung S., Chen H., Leung I., Bonzon C., et al. Accelerated clearance of IgE in chimpanzees is mediated by XmAb7195, an Fc-engineered antibody with enhanced affinity for inhibitory receptor FcγRIIb. Am J Respir Crit Care Med 2014, 189:A4261.
48. Doherty D.G. Immunity, tolerance and autoimmunity in the liver: a comprehensive review. J Autoimmun 2015.
49. Nakar C.T., Bussel J.B. 3G8 and GMA161, anti FcγRIII inhibitory monoclonal antibodies in the treatment of chronic refractory ITP. (Summary of 2 pilot studies). Blood 2009, 114:949.
50. Moore G.L., Chen H., Karki S., Lazar G.A. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. mAbs 2010, 2:181-189.
51. Idusogie E.E., Wong P.Y., Presta L.G., Gazzano-Santoro H., Totpal K., Ultsch M., Mulkerrin M.G. Engineered antibodies with increased activity to recruit complement. J Immunol 2001, 166:2571-2575.
52. Diebolder C.A., Beurskens F.J., de Jong R.N., Koning R.I., Strumane K., Lindorfer M.A., Voorhorst M., Ugurlar D., Rosati S., Heck A.J. Complement is activated by IgG hexamers assembled at the cell surface. Science 2014, 343:1260-1263.
53. de Jong R.N., Beurskens F.J., Verploegen S., Strumane K., van Kampen M.D., Voorhorst M., Horstman W., Engelberts P.J., Oostindie S.C., Wang G. A novel platform for the potentiation of therapeutic antibodies based on antigen-dependent formation of IgG hexamers at the cell surface. PLoS Biol 2016, 14.
54. Scallon B.J., Moore M.A., Trinh H., Knight D.M., Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 1995, 7:251-259.
55. Rother R.P., Rollins S.A., Mojcik C.F., Brodsky R.A., Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007, 25:1256-1264.
56. Stewart R., Hammond S.A., Oberst M., Wilkinson R.W. The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer. J Immunother Cancer 2014, 2:1-10.
57. Bulliard Y., Jolicoeur R., Windman M., Rue S.M., Ettenberg S., Knee D.A., Wilson N.S., Dranoff G., Brogdon J.L. Activating Fcγ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 2013, 210:1685-1693.
58. Simpson T.R., Li F., Montalvo-Ortiz W., Sepulveda M.A., Bergerhoff K., Arce F., Roddie C., Henry J.Y., Yagita H., Wolchok J.D., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013, 210:1695-1710.
59. Selby M.J., Engelhardt J.J., Quigley M., Henning K.A., Chen T., Srinivasan M., Korman A.J. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013, 1:32-42.
60. Dahan R., Sega E., Engelhardt J., Selby M., Korman A.J., Ravetch J.V. FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell 2015, 28:285-295.
61. Wang C., Thudium K.B., Han M., Wang X.T., Huang H., Feingersh D., Garcia C., Wu Y., Kuhne M., Srinivasan M., et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res 2014, 2:846-856.
62. Yang X., Ambrogelly A. Enlarging the repertoire of therapeutic monoclonal antibodies platforms: domesticating half molecule exchange to produce stable IgG4 and IgG1 bispecific antibodies. Curr Opin Biotechnol 2014, 30:225-229.
63. Hezareh M., Hessell A.J., Jensen R.C., van de Winkel J.G., Parren P.W. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1. J Virol 2001, 75:12161-12168.
64. Zalevsky J., Chamberlain A.K., Horton H.M., Karki S., Leung I.W., Sproule T.J., Lazar G.A., Roopenian D.C., Desjarlais J.R. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010, 28:157-159.
65. Baudino L., Nimmerjahn F., Shinohara Y., Furukawa J., Petry F., Verbeek J.S., Nishimura S., Ravetch J.V., Izui S. Impact of a three amino acid deletion in the CH2 domain of murine IgG1 on Fc-associated effector functions. J Immunol 2008, 181:4107-4112.
66. Leabman M.K., Meng Y.G., Kelley R.F., DeForge L.E., Cowan K.J., Iyer S. Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys. mAbs 2013, 5:896-903.
67. Surati M., Patel P., Peterson A., Salgia R. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther 2011, 11:1655-1662.
68. Ernst L.K., van de Winkel J.G., Chiu I.M., Anderson C.L. Three genes for the human high affinity Fc receptor for IgG (FcγRI) encode four distinct transcription products. J Biol Chem 1992, 267:15692-15700.
69. Sautes C., Varin N., Teillaud C., Daeron M., Even J., Hogarth P.M., Fridman W.H. Soluble Fcγ receptors II (FcγRII) are generated by cleavage of membrane FcγRII. Eur J Immunol 1991, 21:231-234.
70. de la Salle C., Esposito-Farese M.E., Bieber T., Moncuit J., Morales M., Wollenberg A., de la Salle H., Fridman W.H., Cazenave J.P., Teillaud J.L., et al. Release of soluble FcγRII/CD32 molecules by human Langerhans cells: a subtle balance between shedding and secretion?. J Invest Dermatol 1992, 99:15S-17S.
71. Ierino F.L., Powell M.S., McKenzie I.F., Hogarth P.M. Recombinant soluble human FcγRII: production, characterization, and inhibition of the Arthus reaction. J Exp Med 1993, 178:1617-1628.
72. Magnusson S.E., Andren M., Nilsson K.E., Sondermann P., Jacob U., Kleinau S. Amelioration of collagen-induced arthritis by human recombinant soluble FcγRIIb. Clin Immunol 2008, 127:225-233.
73. Ellsworth J.L., Hamacher N., Harder B., Bannink K., Bukowski T.R., Byrnes-Blake K., Underwood S., Oliver C., Waggie K.S., Noriega C., et al. Recombinant soluble human FcγR1A (CD64A) reduces inflammation in murine collagen-induced arthritis. J Immunol 2009, 182:7272-7279.
74. Werwitzke S., Trick D., Sondermann P., Kamino K., Schlegelberger B., Kniesch K., Tiede A., Jacob U., Schmidt R.E., Witte T. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fcγ receptor II (CD32). Ann Rheum Dis 2008, 67:154-161.
75. Watanabe H., Sherris D., Gilkeson G.S. Soluble CD16 in the treatment of murine lupus nephritis. Clin Immunol Immunopathol 1998, 88:91-95.
76. Iwata H., Pipi E., Mockel N., Sondermann P., Vorobyev A., van Beek N., Zillikens D., Ludwig R.J. Recombinant soluble CD32 suppresses disease progression in experimental epidermolysis bullosa acquisita. J Invest Dermatol 2015, 135:916-919.
77. Pricop L., Redecha P., Teillaud J.L., Frey J., Fridman W.H., Sautes-Fridman C., Salmon J.E. Differential modulation of stimulatory and inhibitory Fcγ receptors on human monocytes by Th1 and Th2 cytokines. J Immunol 2001, 166:531-537.
78. Okayama Y., Kirshenbaum A.S., Metcalfe D.D. Expression of a functional high-affinity IgG receptor, FcγRI, on human mast cells: up-regulation by IFN-γ. J Immunol 2000, 164:4332-4339.
79. Weflen A.W., Baier N., Tang Q.J., Van den Hof M., Blumberg R.S., Lencer W.I., Massol R.H. Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules. Mol Biol Cell 2013, 24:2398-2405.
80. Sondermann P., Jacob U. Human Fcγ receptor IIb expressed in Escherichia coli reveals IgG binding capability. Biol Chem 1999, 380:717-721.
81. Tillmanns S., Sondermann P., Schrödter A., Schubert C., Nilius S., Buckel P. Soluble Fc-gamma IIb receptor SM101 as potential therapy in autoimmune diseases - results from a Phase 0/Ia clinical trial in healthy volunteers. Ann Rheum Dis 2011, 70:618.
82. Konstaninova T.S., Leonidovna I.V., Hellmann A., Kyrcz-Krzemien S., Tillmanns S., Sondermann P., Buckel P. Interim results from a Phase Ib/IIa clinical trial with the soluble Fc-gamma IIb receptor SM101 for the treatment of primary immune thrombocytopenia. Blood 2012, 120:3388.
83. Tillmanns S., Kolligs C., D'Cruz D.P., Doria A., Hachulla E., Voll R.E., Tansey M., Schollmeier K. SM101, a novel recombinant, soluble, human Fc gamma IIb receptor, in the treatment of systemic lupus erythematosus: results of a double-blind, placebo-controlled multicenter study. Arthritis Rheum 2014, 66:S1238.
84. Roopenian D.C., Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 2007, 7:715-725.
85. Robbie G.J., Criste R., Dall'acqua W.F., Jensen K., Patel N.K., Losonsky G.A., Griffin M.P. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults. Antimicrob Agents Chemother 2013, 57:6147-6153.
86. Ko S.-Y., Pegu A., Rudicell R.S., Yang Z-y, Joyce M.G., Chen X., Wang K., Bao S., Kraemer T.D., Rath T. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 2014, 514:642-645.
87. Saunders K.O., Pegu A., Georgiev I.S., Zeng M., Joyce M.G., Yang Z.Y., Ko S.Y., Chen X., Schmidt S.D., Haase A.T., et al. Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against Simian/Human Immunodeficiency Virus infection. J Virol 2015, 89:5895-5903.
88. Ledgerwood J.E. VRC 606: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), with Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected Adults 2015, ClinicalTrials.gov: NCT02599896.
89. Andrien Jr BA, Sheridan DL, Tamburini PP. Anti-C5 antibodies having improved pharmacokinetics. Patent 2015, US 9,079,949 B1.
90. Vaccaro C., Zhou J., Ober R.J., Ward E.S. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 2005, 23:1283-1288.
91. Challa D.K., Bussmeyer U., Khan T., Montoyo H.P., Bansal P., Ober R.J., Ward E.S. Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis. mAbs 2013, 5:655-659.
92. Levin D., Golding B., Strome S.E., Sauna Z.E. Fc fusion as a platform technology: potential for modulating immunogenicity. Trends Biotechnol 2015, 33:27-34.